– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results